GLP 3 (Retatrutide) — 40 mg

Retatrutide (LY3437943) is a novel triagonist peptide that activates GLP-1, GIP, and glucagon receptors. It is studied for its powerful effects on weight management, glucose regulation, and metabolic health, representing the next generation of incretin-based therapies.

Benefits

• Weight management — studied for profound reductions in body weight in phase 2 trials.
• Glucose control — linked to improved HbA1c and insulin sensitivity in type 2 diabetes.
• Metabolic health — explored for effects on cholesterol, liver fat, and energy balance.
• Multi-pathway synergy — triagonist activity combines GLP-1, GIP, and glucagon benefits.
• Next-gen incretin — represents one of the most advanced peptide approaches in obesity research.

What researchers look at

• Triple receptor agonism: GLP-1, GIP, and glucagon pathways.
• Clinical trials showing record-setting weight loss in obesity and diabetes populations.
• Comparisons with semaglutide and tirzepatide for efficacy and tolerability.
• Investigations into long-term metabolic, cardiovascular, and hepatic outcomes.

Quick Specs

• Form: Lyophilized peptide
• Net per vial: 40 mg
• Purity: ≥99% (HPLC)
• Identity: MS-verified (per COA)
• Storage: 2–8 °C, protect from light

Identity Basics

• Type: Triple GLP-1/GIP/glucagon receptor agonist
• Formula / M.W.: Peptide analog (varies by formulation)
• CAS: 2381089-83-2

Selected Research

• PubChem entry — chemical identity:
  
  https://pubchem.ncbi.nlm.nih.gov/compound/Retatrutide
  
• Phase 2 trial in obesity (NEJM, 2023):
  
  https://pubmed.ncbi.nlm.nih.gov/37323486/
  
• Mechanism of action — triple agonism:
  
  https://pubmed.ncbi.nlm.nih.gov/36006191/
  
• Comparisons with semaglutide/tirzepatide:
  
  https://pubmed.ncbi.nlm.nih.gov/37323485/
  

⚠️ Disclaimer

• This product is intended for laboratory research use only.

• Not for human or veterinary use.

• Not approved for diagnostic, therapeutic, or medical applications.

• Handle using appropriate laboratory safety procedures and personal protective equipment.

  Janoshik COA – Third-Party Testing

• https://janoshik.com/tests/81877-Retatrutide_40mg_4T6EM7GW3ULN
• https://verify.janoshik.com/tests/103224-Retatrutide_VPeptide_Canada_5B9VIARK7F94